Form 4: NewAmsterdam Pharma Director Acquires Shares and RSUs

Director Louis G. Lange reports acquisition of ordinary shares and vesting of restricted stock units in NewAmsterdam Pharma.

Summary

• On April 14, 2025, Louis G. Lange, a director of NewAmsterdam Pharma Co N.V., reported a transaction involving the acquisition of 69 ordinary shares.
• These shares were acquired through the vesting of restricted stock units (RSUs).
• Lange also holds 28,049 ordinary shares indirectly through a trust.
• Additionally, 69 RSUs vested on April 1, 2025, with further vesting scheduled for May and June 2025.
• The RSUs were granted on March 26, 2025, as earnout RSUs related to a business combination agreement.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions, which are neither overwhelmingly positive nor negative. The vesting of RSUs and subsequent share acquisition is a normal part of executive compensation.

Positives

• The vesting of RSUs indicates continued alignment of the director's interests with the company's performance.
• The acquisition of shares, even through vesting, can be seen as a positive sign of confidence in the company's future.

Future Outlook

The remaining RSUs will continue to vest in May and June 2025, subject to the director's continued service.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies, particularly those with equity-based compensation plans.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects the ongoing compensation structure for company directors.

Next Steps

• Continued vesting of remaining RSUs in May and June 2025.

Key Dates

Keywords

NewAmsterdam Pharma, Director, Louis G. Lange, RSU, Ordinary Shares, Beneficial Ownership, Form 4, Vesting, Earnout